Illumina Inc (ILMN)
$432.08 11.53 (2.74%)
18:26 EST ILMN Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 63.52B
PE Ratio 112.23
Volume (Avg. Vol.) 2.23M
Day's Range 406.84 - 434.94
52-Week Range 196.78 - 434.94
Dividend & Yield N/A (N/A)
ILMN Stock Predictions, Articles, and Illumina Inc News
- From InvestorPlace
- From the Web
True, there are political risks in the industry. But there are also lots of growth opportunities for investors in healthcare stocks.
It’s a good time to separate the weak from the strong.
Illumina's news of its $8 billion deal to acquire Grail, a healthcare company focused on cancer detection, has ILMN stock down on Monday.
Illumina (ILMN) news for Monday includes ILMN stock falling on a weak outlook for 2020, as well as some other news about a deal.
You pay a high price for a company with near monopoly like Illumina. ILMN stock has 70% market share, but Its valuation is too high.
Tune in to 'Moneyline' to learn more about new opportunities in biotech stocks and how else to invest in the future of healthcare.
Facebook is reportedly settling with the FTC, Illumina warns on earnings and Amazon Prime Day is nearing in the Nasdaq Today.
Illumina news for Friday concerning early results for the second quarter of 2019 that are below estimates is hitting ILMN stock hard.
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
Alphabet, Fiserv and Caterpillar are three of the 10 stocks you have to sell to sidestep trouble in the immediate future.
The future of genetic medicine is bright, but bumpy. But these bumps will provide many opportunities to buy DNA stocks along the way.
Though most of the stocks in the Nasdaq ETF portfolio delivered strong returns so far this year, a few were the real stars, having gained more than 50%. Compare....
These top-ranked stocks are likely to beat on bottom line in their next releases. Compare Brokers....
These 15 junior-varsity FANG stocks have an opportunity to one day become as big and recognizable as the actual FANG stocks are today.
The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement
The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market
From Talk Markets
Navellier RatingsPowered by Portfolio Grader